Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for BHV-1530 in Urothelial cancers. The expected timing is based on the latest available company guidance and may change.
5/28/25- First patient dosed. 11/10/25:- PR No update. 01/12/26:- Early BHV-1530 Ph1 data show tumor reduction without dose-limiting toxicities; dose escalation ongoing. 03/02/26:- BHV-1530 Phase 1 dose escalation in advanced solid tumors continues; no dose-limiting toxicities observed to date. 05/04/26:- BHV-1530 Phase 1 dose escalation continues in advanced tumors; no dose-limiting toxicities observed to date. 07/20/26:- New Ph1 BHV-1530 data at ESMO Oct 23, 2026. Anti-PD-1 combo cohorts planned H2 2026. 08/10/26:- ESMO 2026 Ph1 data remain expected; Libtayo combo supply agreement announced.
Verification
Confirm timing and program details against the company announcement or filing.